Drug Approval | April 26, 2022
DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Covaxin was earlier approved for children 12-18 years of age
Covaxin was earlier approved for children 12-18 years of age
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)